PIPELINE

Development Pipeline

Technology Therapeutic Area
  • Pre-clinical
  • Phase 1
  • Phase 2
  • Phase 3
POC Target*
VCM** -
Emixustat HCl
PDR***
2017
Stargardt Disease
2018
Intermediate AMD****
2019
Lanosterol Cataract,
Presbyopia
2018
Optogenetics
(Gene Therapy)
Retinitis
Pigmentosa
2019
ACU-6151
(Biomimetic Technology)
AMD, PDR,
DME*****
2020

Technology

VCM** - Emixustat HCl

Therapeutic Area

POC Target*

PDR***

2017

  • Pre-clinical
  • Phase 1
  • Phase 2
  • Phase 3

Therapeutic Area

POC Target*

Stargardt Disease

2018

  • Pre-clinical
  • Phase 1
  • Phase 2
  • Phase 3

Therapeutic Area

POC Target*

Intermediate AMD

2019

  • Pre-clinical
  • Phase 1
  • Phase 2
  • Phase 3

Technology

Lanosterol

Therapeutic Area

POC Target*

Cataract, Presbyopia

2018

  • Pre-clinical
  • Phase 1
  • Phase 2
  • Phase 3

Technology

Optogenetics (Gene Therapy)

Therapeutic Area

POC Target*

Retinitis Pigmentosa

2019

  • Pre-clinical
  • Phase 1
  • Phase 2
  • Phase 3

Technology

ACU-6151 (Biomimetic Technology)

Therapeutic Area

POC Target*

AMD, PDR, DME*****

2020

  • Pre-clinical
  • Phase 1
  • Phase 2
  • Phase 3

  • * POC: Proof of Concept; the years listed are targets. For Stargardt Disease: Initial pharmacodynamic readout only.
  • ** VCM: Visual Cycle Modulator
  • *** PDR: Proliferative Diabetic Retinopathy
  • **** AMD: Age-related Macular Degeneration
  • ***** DME: Diabetic Macular Edema

Therapeutics Development and Disease Indications